Search
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesMethionine
go.drugbank.com/drugs/DB00134ApprovedInvestigationalNutraceuticalA sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Mixtures: Clinimix 2.5% Travasol Aa Without Electrolytes In 10% Dextrose Injec, AA-VenSynonyms: L-a-Amino-g-methylthiobutyric acid, L-MethioninInositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnInositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon. … It is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol.
Balsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approvedBalsam of Peru is a resin that comes from the tree Myroxylon balsamum pereirae. It is constituted by a mixture of substances from which the major components are benzyl cinnamate and [DB00676]. … [L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products.
Mixtures: Arnica De LA Abuela, Stroke II SynergyCategories: Compounds used in a research, industrial, or household settingBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways.
Categories: MATE 2 Substrates with a Narrow Therapeutic Index, OAT3/SLC22A8 Substrates with a Narrow Therapeutic IndexValsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigational[A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States. … In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function.
Synonyms: N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valineMixtures: CARDIK - IN® 160/2.5, CARDIK - IN® 160/2.5Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalneuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. … Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse.
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalFDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the
Respiratory Distress Syndrome
go.drugbank.com/conditions/DBCOND0027916Synonyms: Acute respiratory distress syndrome in adult or childCalcium
go.drugbank.com/drugs/DB01373ApprovedInvestigationalNutraceuticalCalcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. … Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day.
Mixtures: OSSOFORTIN A 70 MG+1200 MG/800 IU TEDAVİ PAKETİ, 4+24 ADET, Multi II IV Vi TabProducts: AAR OS N, Resto L